Pharmacogenomics in breast cancer: Current trends and future directions

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 3, 2004, Pages 296-301

  Wajapeyee, Narendra ^a   Somasundaram, Kumaravel ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Breast cancer; Expression profiling; Genetic variation; Microarray; Pharmacogenomics; Single nucleotide polymorphism

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CYTOCHROME P450; DNA; DRUG METABOLIZING ENZYME; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; MONOCLONAL ANTIBODY; PRODRUG; RECOMBINANT ANTIBODY; TAMOXIFEN; THYMIDYLATE SYNTHASE; TRASTUZUMAB;

AGE; BLOOD TOXICITY; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; DISEASE SEVERITY; DNA MICROARRAY; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TRANSPORT; EARLY DIAGNOSIS; GASTROINTESTINAL SYMPTOM; GENDER; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC VARIABILITY; GERM LINE; HUMAN; LUNG CANCER; NUTRITIONAL STATUS; PATHOGENESIS; PHARMACOGENOMICS; PREDICTION; PREVALENCE; PROBABILITY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT PLANNING;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; MALE; PHARMACOGENETICS; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 3242886801     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Casey G: The BRCA1 and BRCA2 breast cancer genes. Curr Opin Oncol (1997) 9(1):88-93.
2. Ingvarsson S: Molecular genetics of breast cancer progression. Semin Cancer Biol (1999) 9(4):277-228.
3. Hortobagyi GN: Treatment of breast cancer. N Engl J Med (1998) 339(14):974-984.
4. Erichsen HC, Chanock SJ: SNPs in cancer research and treatment. Br J Cancer (2004) 90(4):747-751.
5. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet (1999) 22(3):239-247.
6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 266(5182):66-71.
7. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature (1995) 378(6559):789-792.
8. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst(2002) 94(18):1365-1372.
9. Kainu T, Juo SH, Desper R, Schäffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi OP et al: Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA (2000) 97(17):9603-9608.
10. Wooster R, Weber BL: Breast and ovarian cancer. N Engl J Med (2003) 348(23):2339-2347.
11. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM et al: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 286(5449):2528-2531.
12. Boardman LA, Thibodeau SN, Schaid DJ, Lindor NM, McDonnell SK, Burgart U, Ahlquist DA, Podratz KC, Pittelkow M, Hartmann LC: Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med (1998) 128(11):896-899.
13. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 16(1):64-67.
14. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 250(4985):1233-1238.
15. Lairmore TC, Norton JA: Advances in molecular genetics. Am J Surg (1997) 173(1):37-41.
16. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewskii M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F et al: Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 31(1):55-59.
17. Welcsh PL, Owens KN, King MC: Insights into the functions of BRCA1 and BRCA2. Trends Genet (2000) 16(2):69-74.
18. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 88(2):265-275.
19. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic: cells. Mol Cell (1998) 2(3):317-328.
20. Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R: A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA (2001) 98(6):3232-3236.
21. Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 10(9):955-960.
22. Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science (1999) 286(5439):487-491.
23. Kroemer HK, Eichelbaum M: It's the genes, stupid. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci (1995) 56(26):2285-2298.
24. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev (1997) 6(9):733-743.
25. Maugard CM, Charrier J, Pitard A, Campion L, Akande O, Pleasants L, Ali-Osman F: Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. Int J Cancer (2001) 91(3):334-339.
26. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A: Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev (2001) 10(3):229-236.
27. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA (1992) 89(10):4285-4289.
28. Hynes NE, Stern DF: The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 1198(2-3):165-184.
29. Sundaresan S, Penuel E, Sliwkowski MX: The biology of human epidermal growth factor receptor 2. Curr Oncol Rep (1999) 1(1):116-122.
30. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
31. Sheshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER2-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol (1993) 11(10):1936-1942.
32. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R: HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res (1993) 53(20):4960-4970.
33. Ravdin PM, Chamness GC: The c-ErbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - a review. Gene (1995) 159(1):19-27.
34. Innocenti F, Ratain MJ: Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer (2002) 38(5):639-644.
35. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 55(7):1407-1412.
36. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 15(10):3223-3229.
37. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J (2001) 1(1):65-70.
38. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene in association with its protein expression in human gastrointestinal cancers. Anticancer Res (1999) 19(4B):3249-3252.
39. Somasundaram K, Mungamuri SK, Wajapeyee N: DNA microarray technology and its applications in cancer biology. Appl Genomics Proteomics (2002) 1:209-218.
40. Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg A, Fernö M, Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 61(16):5979-5984.
41. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M et al. Gene expression predictors of breast cancer outcomes. Lancet (2003) 361(9369):1590-1596.
42. Lee JK, Bussey KJ, Gwadry FG, Reinhold W, Riddick G, Pelletier SL, Nishizuka S, Szakacs G, Annereau JP, Shankavaram U, Lababidi S et al: Comparing cDNA and oligonucleotide array data: Concordance of gene expression across platforms for the NCl-60 cancer cells. Genome Biol (2003) 4(12):R82.
43. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX et al: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA (2003) 100(10):5974-5979.
44. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O et al: Molecular portraits of human breast tumours. Nature (2000) 406(6797):747-752.
45. Pusztai L, Ayers M, Simmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN, Stec J: Prospective validation of gone expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Am Soc Clin Oncol (2003) 22:1.
46. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA (2001) 98(19):10869-10874.
47. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA (2003) 100(14):8418-8423.
48. Sotiriou C, Powels TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET: Gone expression profiles derived from fine needle aspiration correlates with the response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 4:R3.
49. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 415(6871):530-536.
50. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M et al: A gene expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 347(25):1999-2009.
51. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks Jr, Nevins JR: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA (2001) 98(20):11462-11467.